Regeneron (REGN) May Be Undervalued After Cemdisiran Drug Review Acceptance

Regulatory Nod Boosts Regeneron's Pipeline Valuation

Regeneron Pharmaceuticals ($REGN) confirmed on Tuesday that both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted its Biologics License Application (BLA) and Marketing Authorization Application (MAA), respectively, for cemdisiran. The drug is under review for the treatment of generalized myasthenia gravis (GMG), a chronic autoimmune neuromuscular disease. This dual regulatory acceptance signals a critical advancement for Regeneron's pipeline and underscores the potential for a new therapeutic option in a market with significant unmet needs.

The announcement immediately spurred investor interest, driving $REGN shares upward by 3.5% to $955.20 by midday trading. Volume for the stock surged to 1.8 million shares, well above its 30-day average of 1.1 million shares, reflecting strong market enthusiasm. This positive sentiment highlights the market's recognition of cemdisiran's potential to become a significant revenue driver for the biotechnology firm.

Market Impact

The acceptance of cemdisiran's regulatory filings propelled $REGN's market capitalization to approximately $104 billion, an increase of roughly $3.5 billion on the news. The 3.5% gain to $955.20 represented the stock's largest single-day percentage increase since October 2023, when positive data from its Eylea HD trials were released. This move pushed $REGN above its 50-day moving average of $942.50, signaling renewed bullish momentum.

Historically, regulatory acceptances for novel drugs often precede periods of sustained investor confidence, particularly in the biotechnology sector. The last time $REGN experienced a similar pipeline-driven uplift of this magnitude was following the initial FDA approval of Dupixent in 2017. This recent ascent positions $REGN to test resistance levels around $975, a price point not consistently held since early Q1 2024.

The positive development for $REGN also had a ripple effect across the broader biotech landscape. The iShares Biotechnology ETF ($IBB) saw a modest gain of 0.8%, while the SPDR S&P Biotech ETF ($XBI) advanced 0.6%, suggesting a sector-wide boost in sentiment regarding pipeline progress. Competitors in the complement inhibitor space, such as Argenx ($ARGX) and Alexion (a subsidiary of AstraZeneca $AZN), saw more muted reactions, with $ARGX down 0.2% and $AZN up 0.1%, as investors weighed the competitive implications of a new entrant.

What Analysts Are Saying

Institutional analysts quickly reacted to Regeneron's regulatory milestone, largely echoing a bullish outlook. According to analysts at JP Morgan, who reiterated an "Overweight" rating and a price target of $1,050, "Cemdisiran's acceptance for review marks a pivotal moment for Regeneron's immunology franchise. With its subcutaneous administration and strong efficacy profile shown in Phase 3 trials, we project cemdisiran could achieve peak annual sales of $1.5 billion to $2 billion, significantly diversifying Regeneron's revenue base beyond Eylea." They emphasized the drug's potential to capture a substantial share of the GMG market, particularly among patients seeking less frequent, self-administered treatment options.

Conversely, analysts at Morgan Stanley, while acknowledging the positive development, maintained a more cautious "Equal-Weight" rating with a price target of $980. "While cemdisiran's regulatory progress is undoubtedly positive, the competitive landscape in GMG and other complement-mediated diseases is intensifying," their note stated. "Existing therapies, including Alexion's Soliris and Ultomiris, and Argenx's Vyvgart, are well-entrenched. Regeneron will need to demonstrate clear differentiation in real-world settings to justify a premium market share capture, especially considering potential pricing pressures." This perspective highlights the challenges of market penetration despite clinical success.

Leerink Partners analysts, in a client note, projected that cemdisiran could add approximately $3 to $5 per share to Regeneron's fair value, contingent on successful approval and market uptake. "The regulatory acceptance de-risks a significant portion of cemdisiran's development pathway," they wrote. "This asset, combined with the strong performance of Dupixent and Eylea HD, reinforces Regeneron's long-term growth trajectory, making the stock appear undervalued at current levels relative to its pipeline potential."

What to Watch

Investors should closely monitor several key catalysts and risk factors in the coming months. The most immediate focus will be on the Prescription Drug User Fee Act (PDUFA) target action date for cemdisiran in the U.S., which is expected in late Q3 2024. A positive decision from the FDA would trigger further upside potential for $REGN shares and solidify its market entry. Similarly, the European regulatory timeline, though typically longer, will provide additional clarity on cemdisiran's global market access.

Beyond regulatory decisions, market penetration and uptake will be crucial. Investors should watch for early commercialization metrics post-approval, including prescription volumes and payer coverage decisions, which will indicate the drug's competitive standing against established therapies. Key support for $REGN shares sits around the $940 level, representing its recent 50-day moving average, while resistance is observed near $975, a level that has proven difficult to break consistently.

Potential risk factors include unexpected clinical trial setbacks for other indications of cemdisiran, or for other pipeline assets, which could temper overall sentiment. Additionally, an increasingly competitive landscape, particularly with new entrants or expanded indications for existing complement inhibitors, could pressure cemdisiran's market share. Broader market downturns or shifts in healthcare policy regarding drug pricing could also impact $REGN's valuation regardless of individual drug performance.